{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:55:51Z","timestamp":1792295751452,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jaip.2021.12.006","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T02:45:13Z","timestamp":1640141113000},"page":"732-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies"],"prefix":"10.1016","volume":"10","author":[{"given":"Bob","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Niederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upender","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Pandit-Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.12.006_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fped.2019.00246","article-title":"Epidemiology of asthma in children and adults","volume":"7","author":"Dharmage","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaip.2021.12.006_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11882-017-0693-2","article-title":"Impact of respiratory virus infections in exacerbation of acute and chronic rhinosinusitis","volume":"17","author":"Tan","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2021.12.006_bib3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaci.2012.05.052","article-title":"Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-\u03b3 and IL-4","volume":"130","author":"Soyka","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaci.2007.10.025","article-title":"Epithelium dysfunction in asthma","volume":"120","author":"Holgate","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(10)61380-3","article-title":"Role of viral respiratory infections in asthma and asthma exacerbations","volume":"376","author":"Busse","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.006_bib6","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1067\/mai.2001.118891","article-title":"Allergic rhinitis and its impact on asthma","volume":"108","author":"Bousquet","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20052448","article-title":"Type 2 immunity is controlled by IL-4\/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system","volume":"203","author":"Voehringer","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib8","first-page":"141","article-title":"Th2 biased upper airway inflammation is associated with an impaired response to viral infection with Herpes simplex virus 1","volume":"54","author":"Lan","year":"2016","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.12.006_bib9","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.12.006_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.006_bib11","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2021.12.006_bib12","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2021.12.006_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.12.006_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.006_bib17","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.006_bib22","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.006_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.006_bib25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2021.12.006_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.12.006_bib28","first-page":"S40","article-title":"Biologics in STAT3 loss-of-function hyper IgE syndrome: a report of 3 cases demonstrating improved clinical outcomes","volume":"40","author":"West","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/JAA.S81541","article-title":"United airway disease: current perspectives","volume":"9","author":"Giavina-Bianchi","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2021.12.006_bib30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2019.06.023","article-title":"Cross-talk between TH2 and TH17 pathways in patients with chronic rhinosinusitis with nasal polyps","volume":"144","author":"Wang","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.006_bib31","doi-asserted-by":"crossref","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","article-title":"TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma","volume":"7","author":"Choy","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib32","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2000024","article-title":"Disseminated coccidioidomycosis treated with interferon-\u03b3 and dupilumab","volume":"382","author":"Tsai","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2017.1367458","article-title":"Airway epithelial barrier dysfunction in the pathogenesis and prognosis of respiratory tract diseases in childhood and adulthood","volume":"5","author":"Yuksel","year":"2017","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jaip.2021.12.006_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaip.2021.12.006_bib35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/all.12627","article-title":"Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells","volume":"70","author":"Contoli","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.12.006_bib36","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","article-title":"IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in\u00a0vivo","volume":"190","author":"Jackson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.12.006_bib37","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1111\/all.14435","article-title":"RV-C infections result in greater clinical symptoms and epithelial responses compared to RV-A infections in patients with CRS","volume":"7","author":"Willis","year":"2020","journal-title":"Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982101374X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982101374X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:34:07Z","timestamp":1761975247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982101374X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S221321982101374X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.12.006","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}